NO953322L - Anvendelse av 1,4-dihydropyridin-3,5-dikarboksylsyreestere som legemidler - Google Patents

Anvendelse av 1,4-dihydropyridin-3,5-dikarboksylsyreestere som legemidler

Info

Publication number
NO953322L
NO953322L NO953322A NO953322A NO953322L NO 953322 L NO953322 L NO 953322L NO 953322 A NO953322 A NO 953322A NO 953322 A NO953322 A NO 953322A NO 953322 L NO953322 L NO 953322L
Authority
NO
Norway
Prior art keywords
dihydropyridine
drugs
dicarboxylic acid
acid esters
esters
Prior art date
Application number
NO953322A
Other languages
English (en)
Other versions
NO953322D0 (no
Inventor
Klaus Urbahns
Otto Behner
Siegfried Goldmann
Hans-Georg Heine
Bodo Junge
Rudolf Schone-Loop
Egbert Wehinger
Hartmund Wollweber
Henning Sommermeyer
Thomas Glaser
Reilinde Wittka
Jean-Marie-Viktor De Vry
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO953322D0 publication Critical patent/NO953322D0/no
Publication of NO953322L publication Critical patent/NO953322L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO953322A 1994-08-25 1995-08-24 Anvendelse av 1,4-dihydropyridin-3,5-dikarboksylsyreestere som legemidler NO953322L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4430094A DE4430094A1 (de) 1994-08-25 1994-08-25 Verwendung von 3,5-Dicarbonsäureester-1,4-Dihydropyridinen als Arzneimittel

Publications (2)

Publication Number Publication Date
NO953322D0 NO953322D0 (no) 1995-08-24
NO953322L true NO953322L (no) 1996-02-26

Family

ID=6526498

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953322A NO953322L (no) 1994-08-25 1995-08-24 Anvendelse av 1,4-dihydropyridin-3,5-dikarboksylsyreestere som legemidler

Country Status (14)

Country Link
US (2) US5665741A (no)
EP (1) EP0705819A1 (no)
JP (1) JPH0859468A (no)
KR (1) KR960007563A (no)
CN (1) CN1128757A (no)
AU (1) AU3011295A (no)
CA (1) CA2156673A1 (no)
DE (1) DE4430094A1 (no)
EE (1) EE9500055A (no)
FI (1) FI953957A (no)
HU (1) HUT74617A (no)
IL (1) IL115030A0 (no)
NO (1) NO953322L (no)
PL (1) PL310146A1 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5568200A (en) * 1999-06-23 2001-01-09 Ajinomoto Co., Inc. Dihydropyridine derivative
CN1939307A (zh) * 2002-02-05 2007-04-04 安斯泰来制药有限公司 2,4,6－三氨基－1,3,5－三嗪衍生物
US20050075359A1 (en) * 2003-03-14 2005-04-07 Rikako Kono Large conductance calcium-activated K channel opener
AU2012342226B2 (en) * 2011-11-24 2017-09-28 Richter Gedeon Nyrt. 1,4- dihydropyridine derivatives with Hsp modulating activity
CN104710441B (zh) * 2014-12-18 2017-01-18 苏州科技学院 吡啶五甲酸二钾化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1813436C3 (de) * 1968-12-07 1979-01-11 Bayer Ag, 5090 Leverkusen N-Substituierte 2,6-Dimethyl-l,4dihydropyridine
DE1923990C3 (de) * 1969-05-10 1978-11-23 Bayer Ag Verfahren zur Herstellung von N-substituierten M-Dihydropyridin-S.S-dicarbonsäureestern
US3883543A (en) * 1969-05-10 1975-05-13 Bayer Ag N-alkyl-1,4-dihydropyridines
JPS4899181A (no) * 1972-04-04 1973-12-15
DE2815578C2 (de) * 1978-04-11 1986-01-16 Bayer Ag, 5090 Leverkusen Neue pharmazeutische Verwendung von Nimodipin
AU1570588A (en) * 1987-03-27 1988-11-02 Byk Gulden Lomberg Chemische Fabrik Gmbh New intermediate products and process
DE4011695A1 (de) * 1990-04-11 1991-10-17 Bayer Ag Verwendung von n-alkylierten 1,4-dihydropyridindicarbonsaeureestern als arzneimittel, neue verbindungen und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
KR960007563A (ko) 1996-03-22
HUT74617A (en) 1997-01-28
NO953322D0 (no) 1995-08-24
IL115030A0 (en) 1995-12-08
EP0705819A1 (de) 1996-04-10
CN1128757A (zh) 1996-08-14
JPH0859468A (ja) 1996-03-05
FI953957A0 (fi) 1995-08-23
PL310146A1 (en) 1996-03-04
HU9502509D0 (en) 1995-10-30
DE4430094A1 (de) 1996-02-29
US5955482A (en) 1999-09-21
EE9500055A (et) 1996-04-15
FI953957A (fi) 1996-02-26
CA2156673A1 (en) 1996-02-26
AU3011295A (en) 1996-03-07
US5665741A (en) 1997-09-09

Similar Documents

Publication Publication Date Title
ATE211131T1 (de) Arylsulfonylaminohydroxamsäurederivate
ATE257846T1 (de) Herstellung von inulinhaltigen produkten
DE69512053D1 (de) Selektive herstellung von para-dialkylsubstituierten benzolderivaten
ATE255819T1 (de) Zusammensetzungen von süssigkeiten
NO953367L (no) Anvendelse av substituerte 4-fenyl-6-amino-nikotinsyre-derivater som legemidler
IT8848259A0 (it) 1,4-diidropiridine, loro procedimento di preparazione e loro applicazione come medicamenti
FI951388A (fi) Substituoidut heterosykliset karboksyylihappoamidiesterit, niiden valmistus ja niiden käyttö lääkeaineina
NO953322D0 (no) Anvendelse av 1,4-dihydropyridin-3,5-dikarboksylsyreestere som legemidler
FI941149A0 (fi) 2,4-diamino-3-hydroksikarboksyylihapon johdannaisia
DE69502395D1 (de) Herstellung von triarylboran
NO960777D0 (no) Anvendelse av N-alkylerte 1,4-dihydropyridin dikarboksylsyreestere som medikamenter
DE69705860D1 (de) Herstellung von adipinsäure
FI932396A0 (fi) Foerfarande foer framstaellning av en dubbelskyddad 2,3-hydroximetylcyklobutanol
DE69817868D1 (de) 4-fluoro-3-oxocarbonsäureester und ihre herstellung
ZA93210B (en) Specific 1,4-dihydropyridine-3, 5-dicarboxylic acid ester, process for its preparation and its pharmaceutical use.
DK0876367T3 (da) Trans apovincaminsyreesterderivater som lægemidler
DE69305250D1 (de) Herstellung von Alkandicarbonsäurederivaten
KR950702115A (ko) 디히드로피리딘 유도체의 신규 의약 용도(novel medicinal use of dihydropyridine derivative)
DE69609219D1 (de) Peroxycarbonsäureester Photoinitiatoren abgeleitet von Stickstoff-Heterozyklen
DE59504642D1 (de) Herstellung von carbaminsäurevinylestern
DE69527684D1 (de) Herstellung von 3-oxy-5-oxo-6-Heptensäurederivaten
DE69611546D1 (de) Herstellung von 2,6-dimethylnaphthalin
DE69502982D1 (de) Herstellung geschützter Aminothiazolylessigsäurederivate
NO20011499L (no) Fremgangsmåte for fremstilling av 6,6-dialkoksy-5-hydroksy-3- oksoheksansyreestere
ATE204573T1 (de) Dihydrat von (2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3- henylpropionsäure ester von 4,10-beta- diacetoxy-2alpha-benzoyloxy-5beta, 20-epoxy-1- hydroxy-9-oxo-19-nor-cyclopropa(g)tax-11-en- 13alpha-yl und verfahren zu ihrer herstellung